Blood Biomarkers from Research Use to Clinical Practice: What Must Be Done? A Report from the EU/US CTAD Task Force.

Angioni, D; Delrieu, J; Hansson, O; Fillit, H; Aisen, P; Cummings, J; Sims, J R; Braunstein, J B; Sabbagh, M; Bittner, T; Pontecorvo, M; Bozeat, S; Dage, J L; Largent, E; Mattke, S; Correa, O; Gutierrez Robledo, L M; Baldivieso, V; Willis, D R; Atri, A; Bateman, R J; Ousset, P-J; Vellas, B; Weiner, M

Angioni, D; Delrieu, J; Hansson, O; Fillit, H; Aisen, P; Cummings, J; Sims, J R; Braunstein, J B; Sabbagh, M; Bittner, T; Pontecorvo, M; Bozeat, S; Dage, J L; Largent, E; Mattke, S; Correa, O; Gutierrez Robledo, L M; Baldivieso, V; Willis, D R; Atri, A; Bateman, R J; Ousset, P-J; Vellas, B; Weiner, M.

Affiliation

Angioni D; Davide Angioni, Gerontopole of Toulouse, Alzheimer's Disease Research and Clinical Center, Toulouse University Hospital, Toulouse, France, davideangioni2@gmail.com.

J Prev Alzheimers Dis ; 9(4): 569-579, 2022.

Article in En | MEDLINE | ID: mdl-36281661

Subject(s)

Alzheimer Disease; Humans; Alzheimer Disease/drug therapy; Biomarkers; Advisory Committees

Key words

Alzheimer's disease; amyloid; blood biomarkers; clinical trials; diagnostic; neurofilament light; p-tau

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Alzheimer Disease Limits: Humans Language: En Journal: J Prev Alzheimers Dis Year: 2022 Document type: Article Country of publication: Switzerland

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google